Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1625288/000149315222003407/form10-q.htm
SEC Filings
NXEN Annual Reports
NXEN Quarterly Reports
10-Q Quarterly Report May 2022
10-Q Quarterly Report February 2022
10-Q Quarterly Report May 2021
10-Q Quarterly Report February 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report February 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report May 2022
10-Q Quarterly Report February 2022
10-Q Quarterly Report May 2021
10-Q Quarterly Report February 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report February 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report May 2019
NXEN Corporate News
Financial Exhibit
New Agreement
New Financial Obligation
Unregistered Sales January 2022
Financial Exhibit
Regulated Disclosure July 2020
Event for Officers April 2020
Event for Officers October 2019
Financial Exhibit
Regulated Disclosure July 2019
Event for Officers April 2019
Vote of Security Holders March 2019
Financial Exhibit
Regulated Disclosure March 2019
Financial Exhibit
Regulated Disclosure March 2019
Financial Exhibit
Regulated Disclosure February 2019
Financial Exhibit
New Agreement
New Financial Obligation
Unregistered Sales
New Agreement
New Financial Obligation
Unregistered Sales
January 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
July 2020
Event for Officers
April 2020
Event for Officers
October 2019
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
July 2019
Event for Officers
April 2019
Vote of Security Holders
March 2019
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
March 2019
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
March 2019
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
February 2019
Last10K.com | 10-Q Quarterly Report Tue Feb 08 2022
Cover - shares | 6 Months Ended | |
|---|---|---|
Dec. 31, 2021 | Feb. 04, 2022 | |
| Cover [Abstract] | ||
| Document Type | 10-Q | |
| Amendment Flag | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Dec. 31, 2021 | |
| Document Fiscal Period Focus | Q2 | |
| Document Fiscal Year Focus | 2022 | |
| Current Fiscal Year End Date | --06-30 | |
| Entity File Number | 000-55320 | |
| Entity Registrant Name | NEXIENBIOPHARMA, INC. | |
| Entity Central Index Key | 0001625288 | |
| Entity Tax Identification Number | 26-2049376 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Address, Address Line One | 4340E Kentucky Ave. | |
| Entity Address, Address Line Two | Suite 206 | |
| Entity Address, City or Town | Glendale | |
| Entity Address, State or Province | CO | |
| Entity Address, Postal Zip Code | 80246 | |
| City Area Code | (303) | |
| Local Phone Number | 495-7583 | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | true | |
| Elected Not To Use the Extended Transition Period | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 60,022,196 |
View differences made from one quarter to another to evaluate Nexien Biopharma, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Nexien Biopharma, Inc..
Assess how Nexien Biopharma, Inc.'s management team is paid from their Annual Proxy
Nexien Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
Tools
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited)
Consolidated Statements Of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)
Commitments And Contingencies
Convertible Notes Payable
Convertible Notes Payable (Details Narrative)
Going Concern Uncertainty
Going Concern Uncertainty (Details Narrative)
License Agreements
License Agreements (Details Narrative)
Nature Of Business And Basis Of Presentation
Related Party Transactions
Related Party Transactions (Details Narrative)
Schedule Of Fair Value Of Stock Options Assumptions (Details)
Schedule Of Fair Value Of Warrants Assumptions (Details)
Schedule Of Stock Option Activity (Details)
Schedule Of Warrants Outstanding (Details)
Share Exchange Agreement
Share Exchange Agreement (Details Narrative)
Stockholders??? Equity
Stockholders??? Equity (Details Narrative)
Stockholders??? Equity (Tables)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Material Contracts, Statements, Certifications & more
Nexien Biopharma, Inc. provided additional information to their SEC Filing as exhibits
Ticker: NXEN
CIK: 1625288
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-003407
Submitted to the SEC: Tue Feb 08 2022 6:07:46 AM EST
Accepted by the SEC: Tue Feb 08 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/nxen/0001493152-22-003407.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
SEC Filing Financial Summary
Excel Download
Loading SEC Filing Financial Summary...